POSTTRAUMATIC STRESS DISORDER – THE NEUROSCIENTIFIC BASIS OF EVIDENCE-BASED TREATMENTS*

George E. Jaskiw
Psychiatry Service, Louis Stokes Cleveland DVAMC, Department of Psychiatry, Case Western Reserve University, gxj5@case.edu

Posttraumatic stress disorder (PTSD) is a relatively common anxiety spectrum syndrome, in which memory of a triggering trauma becomes aberrantly linked to autonomic and emotional arousal. The recurrent, internally generated stress response can produce enduring behavioral and brain changes. Mechanistically, this may involve both dysregulation of the hypothalamo-pituitary-adrenal axis as well as degradation of the capacity of supramodal cortical areas to process and manage trauma-related emotional content. The optimal balance of information processing and hence behavioral reactivity shifts from the reflective prefrontal cortex in favor of the more emotionally reactive amygdala. Trauma-focused therapies exploit adaptive neuroplasticity to decouple the memory of the trauma from the aberrant emotional and behavioral responses, in effect reconfiguring brain networks. The effect-size of such psychological therapies is generally larger than that for pharmacological treatments which are currently limited to drugs repurposed for PTSD. Nonetheless, in a significant number of patients, some symptoms can be at least partially attenuated by selective serotonin reuptake inhibitors. In addition, the frequency and intensity of trauma-related nightmares can usually be lowered by adrenergic alpha-1 receptor agonists. Even as novel modalities continue to be developed, the judicious implementation of currently available evidence-based treatments for PTSD can target the underlying neurobiology, provide symptomatic relief, and promote psychosocial recovery.

Key words: memory, prefrontal cortex, amygdala, autonomic, neural, network

* за матеріалами пленарної доповіді, виголошеної під час симпозіуму Medicine Updates 2017 SMART LION 5 жовтня 2017 р. у м. Львові
Introduction

Posttraumatic Stress Disorder (PTSD) is an anxiety spectrum syndrome that was added to the International Classification of Diseases and Related Health Problems version 9 (ICD-9) in 1978 and to the Diagnostic and Statistical Manual – III (DSM-III) in 1980 (American Psychiatric Association, 1980; World Health Organization, 1978). As is the case for other psychiatric disorders, the nosology of PTSD is currently based in phenomenology, that is in the emergence and course of nonspecific and often variable symptoms and not in reproducible neurobiological indices (Kendler, 2009; Stephan et al., 2016). While diagnostic elements have varied over time, criteria common to DSM-5 and ICD-10 include a) exposure to a significant traumatic event, b) intrusive recollections, c) avoidant symptoms d) increased physiological arousal (in ICD-10, arousal may be replaced by element of amnesia for the traumatic event) (American Psychiatric Association, 2013; World Health Organization, 1993) (Table 1). The trauma must be significant, but can be experienced directly or indirectly (Table 2).

In the United States (US), the estimated lifetime prevalence of exposure to at least one qualifying trauma is 70-90%, with most people experiencing two or more traumatic events (Kilpatrick et al., 2013; Resnick et al., 1993). The estimated risk of developing PTSD after a single traumatic exposure is 10-30%, with a higher risk associated with violent (e.g. rape, combat) or repeated trauma (Breslau et al., 1998; Friedman et al., 2007a; Grinage, 2003; Kilpatrick et al., 2013). While the reported prevalence of PTSD varies with diagnostic criteria, the quality of data collection and particularly on the population sampled, PTSD is estimated to affect some 8-10% of the adult civilian population in the US (Breslau et al., 1998; Grinage, 2003; Kessler et al., 2012; Kessler et al., 1995) and up to 16% of deployed personnel in the US Armed Forces (Gates et al., 2012). It is more common in women (Breslau et al., 1998; Kessler et al., 1995).

Neurobiology

Since the majority of individuals exposed to significant trauma do not develop PTSD, the disorder can be considered as a deviation from the normative course of recovery. The expected weakening of the association between the initial traumatic event(s) and the acute psychological and biological reactions does not occur. In addition, the autonomic and emotional concomitants become decoupled from the initial trauma and can subsequently be triggered either by external or internal stimuli. Mechanistically, this reflects a maladaptive neuroplasticity of synaptic connections.

Repeated stimulation increases the efficiency of synaptic transmission (Hebb, 1949). “Neurons wire together if they fire together” (Lowel and Singer, 1992). While numerous brain circuits are potentially available for activation at any given moment, the precise activation pattern is dynamically determined ‘on the fly’ by internally- and externally-driven demands (Cole et al., 2013). In the case of PTSD, the repeated activation of circuits linking the traumatic memory with emotional and behavioral responses, becomes excessively facilitated.

Under normal conditions, information about a given event enters the brain where it can be briefly retained in short-term memory and then, depending on other factors, may be encoded, consolidated and stored in long-term memory until it is retrieved (Figure 1) (Lewis, 1979).
The full memory may integrate not just the facts about a given event (declarative memory - where and what happened) but also emotional value (pleasure, threat) and sensory concomitants (visual, olfactory, auditory, etc.). In PTSD, at least some of these elements become aberrantly linked to autonomic and other responses which initially cause and then are reinforced by chronic brain-based behavioral and cognitive changes (Figure 2).

The human brain can be broadly conceptualized as having three phylogenetically, anatomically and functionally different systems, namely primary, limbic and neocortex; these interact at multiple levels (Figure 3).

While all are neuroplastic, the complexity and responsiveness of their neuroplasticity to voluntary control increases from brainstem to neocortex. The neocortex is also distinguished by regional specialization for information processing (Benson, 1993). Executive function, that is the allocation of overall attention as well as integration of information from multiple brain levels, is mediated within the prefrontal cortex (PFC). This phylogenetically unique region and particularly its layer III subserve enhanced information processing capabilities (Amatrudo et al., 2012) which constitute the most distinguishing functional feature of the human brain (Elston et al., 2006). Unfortunately, such specialization is accompanied by a heightened vulnerability to homeostatic imbalance.

Preclinical studies demonstrate that neurochemical changes induced by acute stress immediately degrade the ability of the PFC to provide executive function; repeated bouts of uncontrollable stress can lead to long-term structural changes such as impoverishment of the dendritic arbor and spines of PFC pyramidal cells, particularly those of layer III (Arnsten et al., 2015; McEwen and Morrison, 2013). A preliminary postmortem investigation has identified analogous structural and molecular changes in dendritic spines of pyramidal cells in the PFC of PTSD patients (Young et al., 2015). Converging high resolution imaging data suggest that trauma-related changes in frontal cortex gray matter correlate with certain domains of PTSD (Averill et al., 2017; O’Doherty et al., 2017; Wrocklage et al., 2017). PTSD-related changes in gray matter of amygdala and hippocampus have also been reported (Akiki et al., 2017; Pietrzak et al., 2015). Such structural changes would be expected to tip the balance for cognitive processing from the deliberative, reflective prefrontal cortex (PFC) in favor of more reflexive emotional and behavioral responses generated by subcortical regions such as the amygdala (Arnsten et al., 2015). Not surprisingly, patients with PTSD demonstrate atypical dynamic measures of connectivity across circuits involving the frontal cortex, hippocampus and amygdala (Abdallah et al., 2017; Etkin and Wager, 2007; Jin et al., 2017), resulting in excessive activity by the amygdala and an exaggerated perception of and response to threat (Etkin and Wager, 2007). Indirect transcriptome data suggest that low grade neuroinflammation may contribute to the brain changes (Breen et al., 2017).

Stress-induced autonomic arousal also activates the hypothalamo-pituitary-adrenal (HPA) axis (McEwen, 2007). Several groups have reported elevations of corticotrophin releasing factor or of cortisol in the cerebrospinal fluid of patients with PTSD (Baker et
al., 2005; Baker et al., 1999; Bremner et al., 1997) at times in the face of normal peripheral measures in plasma or urine (Baker et al., 2005; Baker et al., 1999). Despite the variability between studies, the overall data implicating endurability of the HPA axis in at least some patients with PTSD.

### Treatment

Currently, no pharmacological treatments specifically target either symptoms of PTSD (Table 3) or its suspected pathophysiology (Girgenti et al., 2017; Krystal et al., 2017). Serendipity and clinical experimentation have, however, resulted in the repurposing of several already available drug types. Clinicians familiar with the anxiolytic properties of tricyclic as well as monoamine-oxidase inhibitor (MAOI) antidepressants began using them in small numbers of patients with PTSD (Bleich et al., 1986; Burststein, 1981). Encouraging case reports prompted a randomized, double-blind, placebo-controlled clinical trial. In a preliminary sample of male veterans with PTSD related to their service during the Vietnam war, both phenelzine and imipramine were found to be superior to placebo in relieving distress related to intrusive phenomena (nightmares, flashbacks, recollections) but not in addressing non-specific anxiety or avoidance (Frank et al., 1988). The results were confirmed in the full patient sample with phenelzine showing a modest advantage over imipramine (Kosten et al., 1991). The potential side effects and dietary measures associated with MAOI use, however, limited the appeal of this drug class.

The emerging availability of serotonin reuptake inhibitors (SSRIs) with a more favorable side-effect profile and better tolerability prompted their ad hoc use in small groups of patients. Subsequently, in a seminal, double-blind, placebo-controlled 12-week trial, sertraline proved superior to placebo in attenuating avoidance and numbing, but was less effective against hyperarousal (Brady et al., 2000). Additional findings were that i) sertraline was generally well tolerated, ii) attendant symptomatic relief evolved slowly and iii) the placebo response (32%) was surprisingly large (Brady et al., 2000). Furthermore, while significantly more patients in the sertraline group reached predetermined criteria for treatment response (53%), overall the effects were quite modest and many patients showed incomplete symptom resolution (Brady et al., 2000). Comparable double-blind placebo-controlled trials demonstrated that paroxetine was also effective against several groups of symptoms (reexperiencing, avoidance/numbing, hyperarousal) (Marshall et al., 2001; Tucker et al., 2001). A relatively high placebo response rate and the persistence of significant symptoms in many patients were also noted (Tucker et al., 2001). The US Food and Drug Administration approved sertraline (1999) and paroxetine (2001) for the treatment of PTSD. Over the subsequent decade, other SSRIs as well as serotonin and norepinephrine uptake inhibitors (SNRIs) were similarly tested. A recent meta-analysis confirmed that while several of these drugs (fluoxetine, paroxetine, venlafaxine) are superior to placebo in attenuating PTSD symptoms, the effect size is rather small (0.23) and they are associated with significant side-effects, most commonly gastrointestinal distress, weight gain and sexual dysfunction (Hoskins et al., 2015). Furthermore, PTSD symptoms resulting from combat trauma as opposed to civilian trauma may be more resistant to SSRIs (Friedman et al., 2007b; Zohar et al., 2002).

Sleep problems are common and distressing features of PTSD. Recurring nightmares of the triggering event constitute one of several possible elements of intrusive recollection and contribute to sleep disturbances in some 70% of patients (Ohayon and Shapiro, 2000). Early case reports on the salutary effects of prazosin, an α1-adrenergic receptor antagonist (Raskind et al., 2000), prompted a larger, retrospective study. In combat veterans, prazosin significantly reduced the intensity and frequency of severe nightmares associated with chronic PTSD (Raskind et al., 2002). This was confirmed in a placebo-controlled 20-week double-blind crossover protocol (Raskind et al., 2003) and a later placebo-controlled, 8 week, parallel design trial (Raskind et al., 2007). The data unequivocally demonstrated that if prazosin were introduced at a dose of 1 mg/HS and elevated gradually at the rate of 1 mg/HS/week until either adequate symptom relief was achieved or untoward side effects (most commonly sedation or hypotension) limited further increases, the medication was generally well-tolerated, reduced traumatic nightmares, restored normal dreaming and could improve other PTSD symptoms as well as functional status (Raskind et al., 2000;
Raskind et al., 2007; Raskind et al., 2003; Raskind et al., 2002). The minimum recommended target dose of 6 mg/d was well below the mean doses achieved (13 mg/d) in some studies (Raskind et al., 2007). Unfortunately, despite this consistent body of data and the large treatment effect size (~ 1.0) (Raskind et al., 2007), prazosin remains underutilized even in clinical settings familiar with PTSD. A review of a computerized record system in a large US veteran’s hospital showed that 20% of patients with PTSD-associated nightmares never filled their initial prazosin prescription and that only 14% of patients attained the minimum guideline recommended dose of 6 mg/d (Alexander et al., 2015).

Pharmacological responsiveness of symptoms may provide clues about underlying neurobiology. The receptor profiles of SSRIs, SNRIs and prazosin have prompted investigations of the serotonergic and adrenergic systems. In comparison to controls, subsets of patients with PTSD were found to be more sensitive to the anxiogenic effects of an intravenously administered serotonin type 2C receptor (5HT_{2C}) agonist or an adrenergic α1 receptor antagonist (Southwick et al., 1997). This raised the possibility that certain PTSD symptoms in patient subgroups were mediated by hypersensitive 5HT_{2C} receptors; downregulation of these receptors could potentially provide symptomatic relief (Southwick et al., 1997). Analogously, since presynaptic α1 receptors inhibit efflux of noradrenaline, their dysregulation could contribute to excessive activation of postsynaptic α1 receptors in other patient subsets (Kelmendi et al., 2016). This could explain the efficacy of α1-adrenergic receptor antagonists against nightmares. Of course, many other potential contributors to sleep disturbances (e.g., poor sleep hygiene, gastroesophageal reflux syndrome, restless leg syndrome, sleep apnea) should be identified and treated as well (Table 4). The quality of sleep in PTSD can also be improved through cognitive behavioral therapy (Ho et al., 2016).

Several psychotherapies have been developed based on an emerging understanding of how memories are formed and integrated with emotional and behavioral responses. The association between a stimulus and these responses usually weakens during the process of extinction (Pavlov, 1927). In PTSD, this extinction fails. It had long been known that memory consolidation, the process converting information from short term memory to long term memory (Figure 1) depends on protein synthesis (Flexner et al., 1962). It was also believed, however, that initially consolidated memories were relatively fixed. Later preclinical studies demonstrated that with each retrieval of a stored memory, the relevant information had to be reconsolidated via a protein synthesis-dependent mechanism (Debiec et al., 2002; Duvarci et al., 2008; Nader et al., 2000). In other words, storage of a given memory is not necessarily a unique event but rather a process repeated after each retrieval of that memory. As a result, retrieval renders the associative links of a given memory temporarily available for modification at the cellular and systems level (Nader, 2015). Memory itself can be designated as a treatment target.

An astute clinical psychologist observed that that recurring, distressing thoughts in PTSD could be permanently attenuated, if the subject’s eyes were automatically moving in a multi-saccadic manner while the disturbing thought was being held in consciousness (Shapiro, 1989, 1996). The declarative or explicit memory, that is the facts of the traumatic event, was not abolished, but its intrusive nature and attendant autonomic and emotional concomitants were removed. This catalyzed the development of Eye Movement Desensitization and Reprocessing therapy (EMDR) (Bisson et al., 2007; Jeffries and Davis, 2013). It is thought to exploit the limited capacity of the brain to process information at any given point in time. By deliberately focusing on a sensory stimulus during retrieval of the memory, the individual is less able to attend to its distressing associations. Repetition of this process presumably weakens the links between the declarative memory and its previously distressing autonomic and emotional concomitants. Although the declarative memory remains and can be retrieved at will, it becomes progressively less intrusive and no longer evokes distress.

Analogous neurobiological mechanisms are likely operative in other trauma focused cognitive behavioral therapies (TFCBTs) (Bisson et al., 2007). Stimulus generalization (Pavlov, 1927) for example, may allow irrelevant or neutral stimuli to involuntarily trigger circuits (fear, flight or fight) that generate a maladaptive response (Figure 3). Some psychotherapeutic approaches focus on encouraging patients to rationally examine their symptom
triggers and thus gradually to circumscribe the range of triggering stimuli (Figure 4).

During an evening stroll with his father, a toddler was fatally stung by a black and red snake. The father now fears:

- Particular red/ black snakes
- All snakes
- Ropes / Hoses / Cords
- The dark

![Adaptive vs. Maladaptive](image)

**Figure 4: Stimulus Generalization**

Due to their relatively large effect sizes (~1.0), tolerability and favorable side-effect profile (Cusack et al., 2016) EMDR and TFCBTs have been designated as first line treatments for PTSD, ahead of pharmacological approaches (Tol et al., 2014). It is particularly exciting that in preliminary studies, successful EMDR and TFCBTs measurably changed memory-driven activation of brain circuits implicated in emotional processing (Fonzo et al., 2017a; Fonzo et al., 2017b; Malejko et al., 2017; Thomas et al., 2016) and promoted normalization of cortical gray matter (Boukezzi et al., 2017). In other words, when successful, these psychotherapeutic approaches may partially reverse or otherwise mitigate PTSD-induced brain changes that mediate symptoms and disability.

Such analyses inform treatment in other ways. Increasing data support a bi-directional relationship between PTSD and sleep disturbances. Suboptimal quality and quantity of sleep is a non-specific brain stress; even a few days of sleep deprivation or circadian misalignment affect metabolism, appetite, autonomic tone and various inflammatory biomarkers (McEwen and Karatsoreos, 2015). Sleep-disordered breathing is independently associated with changes in the functional connectivity of brain regions (Park et al., 2016) as well as with reductions in brain regional cortical volume (Shi et al., 2017). Such anti-trophic effects on the brain would be expected to augment or even synergize with the primary pathophysiology in PTSD. In turn, PTSD is itself associated with a markedly increased risk of sleep-disturbances (Alexander et al., 2016; Harvey et al., 2003; Ohayon and Shapiro, 2000) including sleep-disordered breathing (e.g. obstructive sleep apnea) (Krakow et al., 2015; Lettieri et al., 2015). This can set up a negative-feedback loop. On the one hand, sleep-disturbances may increase the risk for developing PTSD, exacerbate resulting symptoms and lower the effectiveness of therapies, while on the other hand undertreated PTSD can either cause or exacerbate a host of sleep problems (Gilbert et al., 2015; Short et al., 2017). Conversely, successful pharmacological as well as non-pharmacological treatments of insomnia, nightmares and/or sleep disordered breathing can improve other dimensions and psychosocial outcome in PTSD, perhaps by attenuating hyperarousal, lowering depression and elevating levels of trophic factors (Figure 5) (El-Solh et al., 2017; Krystal et al., 2016; Raskind et al., 2007; Rusch et al., 2015; Vandrey et al., 2014).

![Interactions Between Pathophysiology and Contributing Factors in PTSD](image)

A similar self-reinforcing interaction is seen with substance use disorders; these are both more prevalent in PTSD (Duncan et al., 1996; Pietrzak et al., 2011; Wisco et al., 2016) and associated with chronicity and poor treatment response (McCauley et al., 2012). Some data suggest that initiation and maintenance of substance use may represent a maladaptive attempt to deal with a PTSD-associated symptoms (Vandrey et al., 2014). Concomitant treatment of both disorders should be considered (Flanagan et al., 2016).

**Summary**

The pathophysiology of PTSD is complex but involves genetic, neurohumoral and neurochemical mechanisms as well as neuroinflammatory processes that change the brain at the molecular, structural and functional levels. As is the case for other psychiatric disorders, PTSD is mediated by brain networks rather than by any single neurotransmitter system (Insel, 2010). Suboptimal integration of factual, emotional and other types of information across brain networks results in heterotypical functional connectivity between declarative memories and their autonomic and emotional content. In chronic PTSD, the information-processing capacity of deeper layers of the PFC in particular may become compromised. As a general rule, interventions that promote adaptive neuroplasticity can mitigate or reverse this brain-based pathophysiology and promote...
symptomatic as well as functional recovery (Figure 5). While we await the development of more effective treatments for PTSD (Girgenti et al., 2017), it behooves us to fully integrate and exploit interdisciplinary, evidence-based treatments that are currently available. These include psychotherapeutic approaches such as EMDR and judicious use of psychotropic drugs. When economic, systemic or individual factors (e.g. medication side effects, reluctance to engage in psychotherapy) impede implementation of multimodal approaches, even limited and highly circumscribed efforts (e.g. sleep hygiene to treat sleep disorder, substance use treatment) can prove helpful in most patients. The critical tasks include i) identifying contributing factors and potential treatment targets, ii) determining which treatments are practical under given conditions, iii) continually assessing outcome and adapting treatment efforts.

References

Development of Predictive QSAR Models of 4-Thiazolidinones Antitrypanosomal Activity using Modern Machine Learning Algorithms

1. Abdallah CG, Wrocklage KM, Averill CL, Akiki T, Schweinsburg B, Roy A, Martini B, Southwick SM, Krystal JH, Scott JC. Anterior hippocampal dysconnectivity in posttraumatic stress disorder: a dimensional and multimodal approach. Translational psychiatry. 2017 Feb 1;7(2):e1045.doi: 10.1038/tp.2017.12

2. Akiki TJ, Averill CL, Wrocklage KM, Schweinsburg B, Scott JC, Martini B, Averill LA, Southwick SM, Krystal JH, Abdallah CG. The Association of PTSD Symptom Severity With Localized Hippocampus and Amygdala Abnormalities. Chronic Stress. 2017 Aug;1:2470547017724069. doi: 10.1177/2470547017724069

3. Alexander B, Lund BC, Bernardy NC, Christopher ML, Friedman MJ. Early discontinuation and suboptimal dosing of prazosin: a potential missed opportunity for veterans with posttraumatic stress disorder. The Journal of clinical psychiatry. 2015 May;76(5):e639-44. doi: 10.4088/JCP.14m09057

4. Alexander M, Ray MA, Hébert JR, Youngstedt SD, Zhang H, Steck SE, Bogan RK, Burch JB. The national veteran sleep disorder study: descriptive epidemiology and secular trends, 2000–2010. Sleep. 2016 Jul 1;39(7):1399-410.. doi: 10.5665/sleep.5972

5. Amatrudo JM, Weaver CM, Crimins JL, Hof PR, Rosene DL, Luebeke JI. Influence of highly distinctive structural properties on the excitability of pyramidal neurons in monkey visual and prefrontal cortices. Journal of Neuroscience. 2012 Oct 3;32(40):13644-60. doi: 10.1523/jneurosci.2581-12.2012

6. American Psychiatric Association.. Diagnostic and Statistical Manual of Mental Disorders DSM-III (3rd ed.). Washington DC: American Psychiatric Publishing, Inc. 1980.

7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub; 2013 May 22.

8. Arnsten AF, Raskind MA, Taylor FB, Connor DF. The effects of stress exposure on prefrontal cortex: Translating basic research into successful treatments for post-traumatic stress disorder. Neurobiology of stress. 2015 Jan 31;1:89-99.. doi: 10.1016/j.ynst.2014.10.002

9. Averill LA, Abdallah CG, Pietrzak RH, Averill CL, Southwick SM, Harpaz-Rotem I. Combat Exposure Severity Is Associated With Reduced Cortical Thickness in Combat Veterans: A Preliminary Report. Chronic Stress. 2017 Aug;1:2470547017724714. doi: 10.1177/2470547017724714

10. Baker DG, Ekhtor NN, Kasckow JW, Dashevsky B, Horn PS, Bednarik L, Geracioti Jr TD. Higher levels of basal serial CSF cortisol in combat veterans with posttraumatic stress disorder. American Journal of Psychiatry. 2005 May 1;162(5):992-4. doi: 10.1176/appi.ajp.162.5.992

11. Baker DG, West SA, Nicholson WE, Ekhtor NN, Kasckow JW, Hill KK, Bruce AB, Orth DN, Geracioti Jr TD. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. American Journal of Psychiatry. 1999 Apr 1;156(4):585-8.. doi: 10.1176/ajp.156.4.585

12. Benson DF. Prefrontal abilities. Behavioural neurology. 1993;6(2):75-81. doi: 10.3233/ben-1993-6202

13. Bisson JI, Ehlers A, Matthews R, Pilling S, Richards D, Turner S. Psychological treatments for chronic post-traumatic stress disorder. The British journal of psychiatry. 2007 Feb 1;190(2):97-104.. doi: 10.1192/bjp.bp.106.121402

14. Bleich A, Siegel B, Garb R, Lerer B. Post-traumatic stress disorder following combat exposure: clinical features and psychopharmacological treatment. The British Journal of Psychiatry. 1986 Sep 1;149(3):365-9.

15. Boukezzi S, El Khoury-Malhame M, Auzias G, Reynaud E, Rousseau PF, Richard E, Zendjijdjian X, Roques J, Castelli N, Correard N, Guyon V. Grey matter density changes of structures involved in Posttraumatic Stress Disorder (PTSD) after recovery following Eye Movement Desensitization and Reprocessing (EMDR) therapy. Psychiatry Research: Neuroimaging. 2017 Aug 30;266:146-52. doi: 10.1016/j.psychresns.2017.06.009
16. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. Jama. 2000 Apr 12;283(14):1837-44.

17. Breen MS, Tylee DS, Maihofer AX, Neylan TC, Mehta D, Binder EB, Chandler SD, Hess JL, Kremen WS, Risbrough VB, Woelk CH. PTSD blood transcriptome mega-analysis: shared inflammatory pathways across biological sex and modes of trauma. Neuropsychopharmacology. 2017 Sep 19:npp2017220.. doi: 10.1038/npp.2017.220

18. Bremner JD, Lincinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, Charney DS. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. American Journal of Psychiatry. 1997 May 1;154:624-9.doi: 10.1176/ajp.154.5.624

19. Breslau N, Kessler RC, Chilcoat HD, Schultz LR, Davis GC, Andreski P. Trauma and posttraumatic stress disorder in the community: the 1996 Detroit Area Survey of Trauma. Archives of general psychiatry. 1998 Jul 1;55(7):626-32.

20. Burstein A. Treatment of post-traumatic stress disorder with imipramine. Psychosomatics. 1984 Sep 30;25(9):681-7.

21. Cole MW, Reynolds JR, Power JD, Repovs G, Anticevic A, Braver TS. Multi-task connectivity reveals flexible hubs for adaptive task control. Nature neuroscience. 2013 Sep 1;16(9):1348-55.doi: 10.1038/nn.3470

22. Cusack K, Jonas DE, Forneris CA, Wines C, Sonis J, Middleton JC, Feltner C, Brownley KA, Olmsted KR, Greenblatt A, Weil A. Psychological treatments for adults with posttraumatic stress disorder: A systematic review and meta-analysis. Clinical psychology review. 2016 Feb 29;43:128-41. doi: 10.1016/j.cpr.2015.10.003

23. Debiec J, LeDoux JE, Nader K. Cellular and systems reconsolidation in the hippocampus. Neuron. 2002 Oct 24;36(3):527-38.

24. Duncan RD, Saunders BE, Kilpatrick DG, Hanson RF, Resnick HS. Childhood physical assault as a risk factor for PTSD, depression, and substance abuse: Findings from a national survey. American Journal of Orthopsychiatry. 1996 Jul 1;66(3):437-48.

25. Duvarci S, Nader K, LeDoux JE. De novo mRNA synthesis is required for both consolidation and reconsolidation of fear memories in the amygdala. Learning & Memory. 2008 Oct 1;15(10):747-55.doi: 10.1101/lm.1027208

26. El-Solh AA, Vermont L, Homish GG, Kufel T. The effect of continuous positive airway pressure on post-traumatic stress disorder symptoms in veterans with post-traumatic stress disorder and obstructive sleep apnoea: a prospective study. Sleep Medicine. 2017 May 31;33:145-50. doi: 10.1016/j.sleep.2016.12.025

27. Elston GN, Benavides — Piccione R, Elston A, Zietsch B, Defelipe J, Manger P, Casagrande V, Kaas JH. Specializations of the granular prefrontal cortex of primates: implications for cognitive processing. The Anatomical Record. 2006 Jan 1;288(1):437-48.

28. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. American Journal of Psychiatry. 2007 Oct;164(10):1476-88. doi: 10.1167/appi.apj.2007.07030504

29. Falcon S, Ryan C, Chamberlain K, Curtis G. Tricyclics: Possible treatment for posttraumatic stress disorder. The Journal of clinical psychiatry. 1985 Sep;46(9):385-388.

30. Flanagan JC, Korte KJ, Killeen TK, Back SE. Concurrent treatment of substance use and PTSD. Current psychiatry reports. 2016 Aug 1;18(8):1-9. doi: 10.1007/s11920-016-0709-y

31. Flexner JB, Flexner LB, Stellar E, Haba G. Inhibition of protein synthesis in brain and learning and memory following puromycin. Journal of neurochemistry. 1962 Nov 1;9(6):595-605.

32. Fonzo GA, Goodkind MS, Oathes DJ, Zaiko YV, Harvey M, Peng KK, Weiss ME, Thompson AL, Zack SE, Lindley SE, Arnow BA. PTSD psychotherapy outcome predicted by brain activation during emotional reactivity and regulation. American Journal of Psychiatry. 2017 Jul 18:appi-jp. doi: 10.1167/appi.apj.2017.16091072

33. Fonzo GA, Goodkind MS, Oathes DJ, Zaiko YV, Harvey M, Peng KK, Weiss ME, Thompson AL, Zack SE, Mills-Finnerty CE, Rosenberg BM. Selective effects of psychotherapy on frontopolar cortical function in PTSD. American Journal of Psychiatry. 2017 Jul 18:appi-jp. doi: 10.1167/appi.apj.2017.16091073

34. Frank JB, Kosten TR, Giller EL, Dan E. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. The American journal of psychiatry. 1988 Oct 1;145(10):1289.

35. Frank JB, Kosten TR, Giller EL, Dan E. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. The American journal of psychiatry. 1988 Oct 1;145(10):1289. doi: 10.1167/appi.apj.145.10.1289

36. Friedman MJ, Resick PA, Keane TM. PTSD: Twenty-five years of progress and challenges. Friedman MJ, Keane TM, Resick PA, editors. Handbook of PTSD: Science and practice. New York Guilford Press; 2007 May 29:376-405.

37. Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. Journal of Clinical Psychiatry. 2007 May; 68(5):711-720.
38. Gates MA, Holowka DW, Vasterling JJ, Keane TM, Marx BP, Rosen RC. Posttraumatic stress disorder in veterans and military personnel: Epidemiology, screening, and case recognition. Psychol Serv. 2012;9(4):351-382. doi: 10.1037/a0027649

39. Girgenti MJ, Hare BD, Ghosal S, Duman RS. Molecular and Cellular Effects of Traumatic Stress: Implications for PTSD. Current psychiatry reports. 2015 Nov 1;19(11):85. doi: 10.1007/s11920-017-0841-3

40. Grinage BD. Diagnosis and management of post-traumatic stress disorder. American Family Physician. 2003 Dec 15;68(12):2401-2408.

41. Harvey AG, Jones C, Schmidt DA. Sleep and posttraumatic stress disorder: a review. Clinical Psychology Review. 2003 May 31;23(3):377-407.

42. Hebb DO. Organization of Behavior. New York: Science Editions. 1949.

43. Ho FY, Chan CS, Tang KN. Cognitive-behavioral therapy for sleep disturbances in treating posttraumatic stress disorder symptoms: A meta-analysis of randomized controlled trials. Clinical psychology review. 2016 Feb 29;43:90-102. doi: 10.1016/j.cpr.2015.09.005

44. Hogben GL, Cornfield RB. Treatment of traumatic war neurosis with phenelzine. Archives of General Psychiatry. 1981 Apr 1;38(4):440-5.

45. Hoskins M, Pearce J, Bethell A, Dankova L, Barbui C, Tol WA, Van Ommeren M, De Jong J, Seedat S, Chen H, Bisson JJ. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. The British Journal of Psychiatry. 2015 Feb 1;206(2):93-100. doi: 10.1192/bjp.bp.114.148551

46. Insel TR. Faulty circuits. Scientific American. 2010 Apr;302(4):44-51.

47. Jeffries FW, Davis P. What is the role of eye movements in eye movement desensitization and reprocessing (EMDR) for post-traumatic stress disorder (PTSD)? A review. Behavioural and cognitive psychotherapy. 2013 May;41(3):290-300. doi: 10.1017/s1352465812000793

48. Jin C, Jia H, Langa P, Rangaprakash D, Li L, Liu T, Hu X, Deshpande G. Dynamic brain connectivity is a better predictor of PTSD than static connectivity. Human Brain Mapping. 2017 Sep 1;38(9):4479-96. doi: 10.1002/hbm.23676

49. Kilpatrick DG, Resnick HS, Milanak ME, Miller MW, Keyes KM, Friedman MJ. National estimates of exposure to traumatic events and PTSD prevalence using DSM – IV and DSM – 5 criteria. Journal of traumatic stress. 2013 Oct 1;26(5):537-47. doi: 10.1002/jts.21848

50. Kosten TR, Frank JB, Dan E, McDougle CJ, Gillner JR EL. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. The Journal of nervous and mental disease. 1991 Jun 1;179(6):366-70

51. Krakow BJ, Ulbarri VA, Moore BA, McIver ND. Posttraumatic stress disorder and sleep-disordered breathing: a review of comorbidity research. Sleep medicine reviews. 2015 Dec 31;24:37-45. doi: 10.1016/j.smrv.2014.11.001

52. Krystal JH, Davis LL, Neylan TC, Raskind MA, Schnurr PP, Stein MB, Vescsicchio J, Shiner B, Gleason TD, Huang GD. It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: A consensus statement of the PTSD Psychopharmacology Working Group. Biological psychiatry. 2017 Oct 1;82(7):e51-9. doi: 10.1016/j.biopsych.2017.03.007

53. Krystal JH, Pietrzak RH, Rosenheck RA, Cramer JA, Vescsicchio J, Jones KM, Huang GD, Vertrees JE, Collins J, Krystal AD. Sleep disturbance in chronic military-related PTSD: clinical impact and response to adjunctive risperidone in the Veterans Affairs cooperative study# 504. The Journal of clinical psychiatry. 2016 Apr;77(4):483-91. doi: 10.4088/JCP.14m09585

54. Lettieri CJ, Williams SG, Collen JF. Obstructive sleep apnea syndrome and post-traumatic stress disorder: Clinical outcomes and impact of PAP therapy. Chest. 2015.
63. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. American Journal of Psychiatry. 2001 Dec 1;158(12):1982-8. doi: 10.1176/appi.ajp.158.12.1982

64. McCauley JL, Killeen T, Gros DF, Brady KT, Back SE. Posttraumatic stress disorder and co-occurring use disorders: Advances in assessment and treatment. Clinical Psychology: Science and Practice. 2012 Sep 1;19(3):283-304. doi: 10.1111/cpsp.12006

65. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiological reviews. 2007 Jul 1;87(3):873-904.doi: 10.1152/physrev.00041.2006

66. McEwen BS, Karatosan IN. Sleep deprivation and circadian disruption. Sleep medicine clinics. 2015 Mar 1;10(1):1-0. doi: 10.1016/j.jsmc.2014.11.007

67. McEwen BS, Morrison JH. The brain on stress: vulnerability and plasticity of the prefrontal cortex over the life course. Neuron. 2013 Jul 10;79(1):16-29. doi: 10.1016/j.neuron.2013.06.028

68. Nader K. Reconsolidation and the Dynamic Nature of Memory. Cold Spring Harb Perspect Biol. 2015;7(10):a021782. doi: 10.1101/cshperspect.a021782

69. Nader K, Schafe GE, Le Doux JE. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature. 2000 Aug 17;406(6797):722-6. doi: 10.1038/35021052

70. O'Doherty DC, Tickell A, Ryder W, Chan C, Hermens DF, Bennett MR, Lagopoulos J. Frontal and subcortical grey matter reductions in PTSD. Psychiatry Research: Neuroimaging. 2017 May 19; 266: 1-9. doi: 10.1016/j.psychresns.2017.05.008

71. Ohayon MM, Shapiro CM. Sleep disturbances and psychiatric disorders associated with posttraumatic stress disorder in the general population. Comprehensive psychiatry. 2000 Nov 1;41(6):469-78. doi: 10.1053/comp.2000.16568

72. Park B, Palomares JA, Woo MA, Kang DW, Macey PM, Yan – Go FL, Harper RM, Kumar R. Disrupted functional brain network organization in patients with obstructive sleep apnea. Brain and behavior. 2016 Mar 1;6(3):e00441. doi: 10.1002/brb3.441

73. Pavlov IP. Conditional reflexes: An investigation of the physiological activity of the cerebral cortex. 1927.

74. Pietrzak RH, Averill LA, Abdallah CG, Neumeister A, Krystal JH, Levy I, Harpaz-Rotem I. Amygdala-hippocampal volume and the phenotypic heterogeneity of posttraumatic stress disorder: a cross-sectional study. JAMA psychiatry. 2015 Apr 1;72(4):396-8. doi: 10.1001/jamapsychiatry.2014.2470

75. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of anxiety disorders. 2011 Apr 30;25(3):456-65.. doi: 10.1016/j.janxdis.2010.11.010

76. Raskind MA, Dobie DJ, Kanter ED, Petrie EC, Thompson CE, Peskind ER. The α1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: A report of 4 cases. The Journal of clinical psychiatry. 2000 Feb;61(2):129-133.

77. Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, Shofe J, O’Connell J, Taylor F, Gross C, Rohde K. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biological psychiatry. 2007 Apr 15;61(8):928-34.doi: 10.1016/j.biopsych.2006.06.032

78. Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE, Dobie DJ, Hoff D, Rein RJ, Straits-Tröster K, Thomas RG. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. American Journal of Psychiatry. 2003 Feb 1;160(2):371-3. doi: 10.1176/appi.ajp.160.2.371

79. Raskind MA, Thompson C, Petrie EC, Dobie DJ, Rein RJ, Hoff DJ, McFall ME, Peskind ER. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. The Journal of clinical psychiatry. 2002 Jul 63(7):565-568.

80. Resnick HS, Kilpatrick DG, Saunders BE, Best CL. Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. Journal of consulting and clinical psychology. 1993 Dec;61(6):984.

81. Rusch HL, Guardado P, Baxter T, Mysliwiec V, Gill JM. Improved sleep quality is associated with reductions in depression and PTSD arousal symptoms and increases in IGF-1 concentrations. Journal of clinical sleep medicine: JCSM: of clinical practice. 2015 Jun 15;10(1):1-0. doi: 10.1016/j.jsmc.2014.11.007

82. Shapiro F. Efficacy of the eye movement desensitization procedure in the treatment of traumatic memories. Journal of traumatic stress. 1989 Apr 1;2(2):199-223.

83. Shapiro F. Eye movement desensitization and reprocessing (EMDR): Evaluation of controlled PTSD research. Journal of Behavior Therapy and Experimental Psychiatry. 1996 Sep 1;27(3):209-18.

84. Shi Y, Chen L, Chen T, Li L, Dai J, Lui S, Huang X, Sweeney JA, Gong Q. A Meta-analysis of Voxel-based Brain Morphometry Studies in Obstructive Sleep Apnea. Scientific Reports. 2017 Aug 30;7(1):10095. doi: 10.1038/s41598-017-09319-6

85. Short NA, Allan NP, Schmidt NB. Sleep disturbance as a predictor of affective functioning and symptom
severity among individuals with PTSD: An ecological momentary assessment study. Behaviour Research and Therapy. 2017 Oct 1;97:146-53. doi: 10.1016/j.brat.2017.07.014
86. Southwick SM, Krystal JH, Bremner JD, Morgan C3, Nicolaou AL, Nagy LM, Johnson DR, Heninger GR, Charney DS. Noradrenergic and serotonergic function in posttraumatic stress disorder. Archives of general psychiatry. 1997 Aug 1;54(8):749-58.
87. Stephan KE, Bach DR, Fletcher PC, Flint J, Frank MJ, Friston KJ, Heinz A, Huys QJ, Owen MJ, Binder EB, Dayan P. Charting the landscape of priority problems in psychiatry, part 1: classification and diagnosis. The Lancet Psychiatry. 2016 Jan 31;3(1):77-83. doi: 10.1016/s2215-0366(15)00361-2
88. Thomaes K, Engelhard IM, Sijbrandij M, Cath DC, Van den Heuvel OA. Degrading traumatic memories with eye movements: a pilot functional MRI study in PTSD. European journal of psychotraumatology. 2016 Dec 1;7(1):31371. doi: 10.3402/ejpt.v7.31371
89. Tol WA, Barbu C, Bisson J, Cohen J, Hijazi Z, Jones L, De Jong JT, Magrini N, Omigbodun O, Seedat S, Silove D. World health organization guidelines for management of acute stress, PTSD, and bereavement: Key challenges on the road ahead. PLoS Medicine. 2014 Dec 16;11(12):e1001769. doi: 10.1371/journal.pmed.1001769
90. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. The Journal of clinical psychiatry. 2001 Nov.;62(11):860-868.
91. Vandrey R, Babson KA, Herrmann ES, Bonn-Miller MO. Interactions between disordered sleep, post-traumatic stress disorder, and substance use disorders. International Review of Psychiatry. 2014 Apr 1;26(2):237-47. doi: 10.3109/09540261.2014.901300
92. Wisco BE, Marx BP, Miller MW, Wolf EJ, Mota NP, Krystal JH, Southwick SM, Pietrzak RH. Probable Posttraumatic Stress Disorder in the US Veteran Population According to DSM-5: Results From the National Health and Resilience in Veterans Study. The Journal of clinical psychiatry. 2016 Nov;77(11):1503-10. doi: 10.4088/JCP.15m10188
93. World Health Organization. International Classification of Diseases and Related Health Problems (ICD-9). Geneva: World Health Organization. 1978.
94. World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. World Health Organization; 1993 Nov 1.
95. Wrocklage KM, Averill LA, Scott JC, Averill CL, Schweinsburg B, Trejo M, Roy A, Weisser V, Kelly C, Martini B, Harpaz-Rotem I. Cortical thickness reduction in combat exposed US veterans with and without PTSD. European Neuropsychopharmacology. 2017 May 31;27(5):515-25. doi: 10.1016/j.euroneuro.2017.02.010
96. Young KA, Thompson PM, Cruz DA, Williamson DE, Selemon LD. BA11 FKBP5 expression levels correlate with dendritic spine density in postmortem PTSD and controls. Neurobiology of stress. 2015 Dec 31;2:67-72. doi: 10.1016/j.ynstr.2015.07.002
97. Zohar J, Amital D, Mlodowick C, Kotler M, Bleich A, Lane RM, Austin C. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of clinical psychopharmacology. 2002 Apr 1;22(2):190-5.